0001140361-24-017374.txt : 20240402
0001140361-24-017374.hdr.sgml : 20240402
20240402210033
ACCESSION NUMBER: 0001140361-24-017374
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240330
FILED AS OF DATE: 20240402
DATE AS OF CHANGE: 20240402
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sukhatme Mayukh
CENTRAL INDEX KEY: 0001750050
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40782
FILM NUMBER: 24816636
MAIL ADDRESS:
STREET 1: C/O UOVANT SCIENCES, INC.
STREET 2: 5151 CALIFORNIA AVENUE, SUITE 250
CITY: IRVINE
STATE: CA
ZIP: 92617
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Roivant Sciences Ltd.
CENTRAL INDEX KEY: 0001635088
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 981173944
STATE OF INCORPORATION: D0
FISCAL YEAR END: 0331
BUSINESS ADDRESS:
STREET 1: CLARENDON HOUSE, 2 CHURCH STREET
CITY: HAMILTON HM11
STATE: D0
ZIP: HM11
BUSINESS PHONE: 441-295-5950
MAIL ADDRESS:
STREET 1: CLARENDON HOUSE
STREET 2: 2 CHURCH STREET
CITY: HAMILTON
STATE: D0
ZIP: HM11
4
1
form4.xml
FORM 4
X0508
4
2024-03-30
0001635088
Roivant Sciences Ltd.
ROIV
0001750050
Sukhatme Mayukh
C/O ROIVANT SCIENCES LTD.
7TH FLOOR, 50 BROADWAY
LONDON
X0
SW1H 0DB
UNITED KINGDOM
true
true
Pres&Chief Investment Officer
true
Common Shares
2024-03-30
4
M
0
729081
A
4018196
D
Common Shares
2024-03-30
4
F
0
366211
10.54
D
3651985
D
Common Shares
1657698
I
By LLC
Capped Value Appreciation Rights
2024-03-30
4
M
0
1856163
6.4
D
2026-03-31
Common Shares
729081
0
D
Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount").
On March 30, 2024, the "knock-in" condition (as defined below) and hurdle price applicable to the remaining 1,856,163 of these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 729,081 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on March 28, 2024.
Includes an award of restricted stock covering Common Shares that is fully vested.
Represents the "net settlement" by the Issuer of CVARs in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of the CVARs.
Reflects an award of restricted stock covering Common Shares ("RSAs") that is fully vested. The award of RSAs is held by a limited liability company (the "LLC") that is owned by a family trust (the "Trust"). The reporting person has investment control over both the LLC and the Trust. The reporting person disclaims beneficial ownership of the reported securities held by the LLC except to the extent of his pecuniary interest therein.
This award of CVARs vested (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date, with a vesting commencement date of December 27, 2019.
By: /s/ Jo Chen, as Attorney-in-Fact for Mayukh Sukhatme
2024-04-02